Report Date: Wednesday, July 15, 2026 (before market open) | Event: 2026Q2 Earnings Call
JNJ enters this report in a very different position than it has for most of the past few years — as a momentum stock. Shares have surged from roughly $207 at the start of 2026 to a fresh all-time high near $269 in early July, before settling around $254-258 heading into the print. Per recent coverage, JNJ shares hit fresh all-time highs of $269 heading into the report and are up more than 24% year-to-date in 2026, with one report noting a 71% total return over the trailing twelve months. That rally has been accompanied by a wave of sell-side price-target increases (RBC to $287, TD Cowen to $300, Guggenheim to $270, Wells Fargo $263, and a May upgrade from Leerink to Outperform with a $265 target that shares have already surpassed), reflecting rising conviction in the growth story but also raising the bar for what the market will consider "good enough."
That means expectations, not just results, matter — a in-line quarter with cautious commentary could disappoint a stock priced for continued acceleration, whereas confirmation of the "double-digit growth by decade-end" narrative would likely be well received.
Sentiment heading in is described as bullish, driven by favorable portfolio reshuffling, solid execution, and positive drug-data readouts.
Q1 was a clean beat-and-raise, and management's tone was confident about acceleration through the year:
Key implication for Q2: management explicitly guided to "fairly consistent operational sales growth throughout the year" with margins improving as the year progresses (launch investment front-loaded in H1, 4Q boosted by a 53rd week). That sets up Q2 as a read on whether the growth is tracking as promised and whether the margin drag from Q1 is beginning to ease.
Innovative Medicine - ICOTYDE (icotrokinra) — the first oral IL-23-targeted peptide for plaque psoriasis, approved and launched in March 2026. Management called it a potential "one of our biggest products ever," and after receiving a permanent J-code on April 1, the ramp in prescriptions/payer access will be a focal point (only ~1,500 scripts were reported as of the Q1 call — investors will want to see this scaling). - TREMFYA — still the fastest-growing IL-23 franchise, guided toward >$10B peak sales; watch for continued IBD share gains and progress on the psoriatic-arthritis structural-damage label expansion. - Oncology depth — DARZALEX, CARVYKTI, TECVAYLI/TALVEY (multiple myeloma), RYBREVANT/LAZCLUZE (lung, plus new head & neck breakthrough designation), and INLEXZO (bladder cancer, which saw a reported 50–90% jump in new patient insertions after its April J-code) are all key growth contributors to monitor for continued share gains. - STELARA erosion — biosimilar competition remains a large drag (~900+ bps headwind); the pace of decline vs. offsetting new-launch strength is central to the segment's reported growth rate. - CAPLYTA (from the Intra-Cellular acquisition) — momentum in adjunctive MDD, with bipolar mania data expected later in 2026 and a >$5B peak sales target.
MedTech - Cardiovascular remains the strongest sub-segment: Abiomed (Impella), Shockwave (IVL), and electrophysiology (VARIPULSE/VARIPULSE Pro post-field ablation platform) all posted double-digit growth in Q1; watch for commentary on the Dual Energy THERMOCOOL SMARTTOUCH SF Catheter U.S. submission and any incremental China volume-based procurement (VBP) impact flagged for H2. - Surgery — soft in Q1 (+1.2%) on competitive and VBP pressure; OTTAVA robotic surgery progress (de novo filing, second IDE trial) is a longer-dated catalyst, not a near-term swing factor. - Vision — U.S. Surgical Vision saw competitive pressure in Q1; management guided to acceleration in H2 behind the TECNIS PureSee U.S. launch. - Orthopaedics separation — J&J continues working toward a mid-2027 separation of DePuy Synthes; any updated timeline or structure commentary would be a key data point, particularly ahead of the December 8, 2026 Enterprise Business Review where more detail on long-term strategy is expected.
Talc litigation remains a persistent, if largely priced-in, overhang. After J&J's third attempt to resolve claims through its LTL Management bankruptcy subsidiary collapsed, litigation has resumed in courts, with a mix of trial outcomes (some in J&J's favor, others large plaintiff verdicts). This is worth monitoring for any reserve changes or commentary, though it's a legacy/idiosyncratic risk rather than an operational one — note it is distinct from the recently revived Tylenol/acetaminophen-autism litigation, which targets Kenvue (the spun-off consumer health company), not JNJ directly, though headlines conflating the two occasionally cause investor confusion. A federal appeals court just revived hundreds of Tylenol-pregnancy lawsuits against Kenvue and retailers this week, reviving media attention on the "Johnson & Johnson" name broadly even though liability now sits with Kenvue.
JNJ currently trades at roughly 22x forward earnings — slightly below the S&P 500 and in line with the large-cap pharma industry average — supported by a 2.09% dividend yield (above the S&P 500 average) and a Dividend King status (55+ consecutive years of increases, per one report, though the company's own materials cite 64 years as of the April increase). Bulls argue the valuation still doesn't fully price in the "double-digit growth by decade-end" algorithm management has laid out.
JNJ heads into Q2 earnings as one of 2026's stronger large-cap healthcare performers, riding a "cleanest growth story in health care" narrative built on a deep, largely de-risked pipeline (ICOTYDE, INLEXZO, TREMFYA, RYBREVANT, plus cardiovascular MedTech assets Abiomed/Shockwave) offsetting the well-understood STELARA patent cliff. The bar has risen alongside the stock — a beat-and-raise similar to Q1's would likely be needed to sustain momentum toward record highs, while any sign of decelerating launch uptake, tariff-driven margin slippage, or softer MedTech end-market commentary could trigger profit-taking after a stock that's already up over 20% year-to-date.